Discovery to Cure
at Yale School of Medicine
December 2013
New Yale Joint Venture Has Single Goal of Curing Ovarian Cancer
 A new joint venture formed between Yale and Novogen  has one goal: fighting ovarian cancer through personalized approaches to chemotherapy. The venture, named CanTx, brings new treatment to the market in a field where no new therapies have been developed in more than 30 years.

Ovarian cancer is not a single disease so it requires a personalized  approach. CanTx will develop variations of a proven cancer-killing compound to target the specific make-up of a patient's cancer.   In addition, a new delivery system will target only cancer cells, avoiding the collateral damage of traditional chemotherapy. Patients will be able to undergo treatment without impact on their quality of life.    
Dr. Gil Mor, M.D., Ph.D., of  Discovery to Cure at Yale School of Medicine will co-lead clinical development efforts in the new venture. This partnership, Mor says, will speed the discovery of new treatments for ovarian cancer from the lab to the patient. "This is the future," he says "academia and industry working together for the benefit of the patient."


Ovarian cancer is the fourth leading cause of cancer deaths in American women, in large part because its symptoms are mild and there is no reliable test to detect the disease in its early stages. Discovery to Cure's research efforts seek to improve prevention, early detection and treatment of women's reproductive cancers. Read more.

750 Supporters Stroll Through Yale Campus Raising More Than $150,00 to Fight Women's Reproductive Cancers
On October 26 more than 750 walkers arrived at Yale's Woolsey Hall to stroll the campus in support of Discovery to Cure.  Beverly Levy, a patient of Discovery to Cure's Dr. Elena Ratner, founded the event as a way to give back to the program that saved her life. Teams of survivors, their families, physicians, researchers and others raised more than $150,000 to continue the research that is advancing the fight against some of the deadliest cancers women face.

Read the New Haven Register Story Here 
The Angelina Jolie Effect:What Every Woman Should Know About Her Genes
More than 100 women gathered at the Jewish Community Center of Woodbridge on October 3rd to learn more about how their genes impact the likelihood that they will develop breast, reproductive or other cancers.  The program, presented by a panel of Yale medical experts helped women better understand their risk factors and provided information about genetic testing and its implications. Presented by: Elena Ratner, M.D. Assistant Professor of Obstetrics, Gynecology and Reproductive Services; Erin Wysong Hofstatter, M.D. Assistant Professor of Medicine; Breast Cancer Program; and Ellen T. Matloff, M.S., C.G.C. Director, Cancer Genetic Counseling, Yale Cancer Center.

To learn more or to schedule a program for your business, civic group or faith community please contact
Read the Middletown Press Article
Save the Date
Thursday, January 23, 2014
The Angelina Jolie Effect: 
What Every Woman Should Know About Her Genes
Presented by a panel of Yale Medical Experts
7:00 p.m.-8:30p.m.
Stamford JCC
Stamford, CT

Monday, May 19, 2014
Hedge Against Cancer Golf Invitational
Country Club of Fairfield
Fairfield, CT

About Discovery to Cure

Discovery to Cure leads the way in the prevention, early detection and treatment of women's reproductive cancers.  The direct connection between the research lab and clinical patient care makes Discovery to Cure truly unique and spurs the development of new treatments for ovarian and other women's reproductive cancers.  Research efforts include molecular and cellular research and clinical trials focusing on new treatments and new approaches to diagnosis and prevention.  Learn more at

Would you like to get involved in Discovery to Cure's lifesaving work?
We welcome volunteers to help us with special events and community outreach.  Please e-mail for more information. 
To make a donation please click here.

Like us on Facebook! 

Please consider forwarding this e-mail to a friend.  
Survivor Story

Beth Thompson(center with, from left, Dr. Thomas Rutherford, her husband Howard and Cokie Roberts at a Discovery to Cure gala) is currently 5 years cancer free after two battles with ovarian cancer.  


Beth Thompson refers to herself as a textbook case, having experienced only very subtle symptoms prior to her diagnosis.  "I take good care of myself and I have a busy career and a husband and teenagers at home.   I was approaching 50 when I started to experience mild symptoms like indigestion, bloating and back pain.  It's my nature to be a good soldier and try to march on, so I just figured  he symptoms were part of getting older. I never connected them to my ovaries." 


She had been to her gynecologist 7 months prior for her annual visit and returned once her symptoms worsened to the point where she knew something was seriously wrong. Her doctor referred her to Discovery to Cure's Dr. Thomas Rutherford whose surgical expertise Thompson credits with saving her life.  "There was a confluence of authorities operating in my life.  First of course was God, then Tom Rutherford and then I was able to participate in a Discovery to Cure clinical trial which helped me become cancer free." Thompson remained cancer free for nearly four years, but then, like most women who survive ovarian cancer, she experienced a recurrence. Once again, thanks to the care she received at Discovery to Cure she is cancer free.


"I have enormous optimism for a long, healthy life and I hope that more women will adopt this attitude when facing this disease.  Everyone at Discovery to Cure was warm and encouraging and I never felt that I was in this by myself.  I know that I received the best care available and will always be grateful."


If you or someone you know is experiencing symptoms, or has been diagnosed with a reproductive cancer and would like to schedule an appointment with a Yale Gynecologic Oncology physician  please call: 



Join Our Mailing List